In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alnylam Takes Platform Monetization to a Whole New and Non-Exclusive Level

Executive Summary

Alnylam's monster deal with Roche for non-exclusive rights to the biotech's RNAi platform across four therapeutic areas sets the bar for technology platform monetization. Not only is Alnylam gaining $331 million in upfront payments, it can turn around and re-license those same rights at any time. Roche is for the first time making a splash in RNAi, which it and other companies are betting will be a new therapeutic modality.

You may also be interested in...



Can CRISPR Make The Jump To Therapeutics?

Biomedical researchers are rapidly adopting the new gene-editing technology CRISPR/Cas9 for lab experiments, but can CRISPR also become the basis for new treatments of human disease? At least two venture-backed start-ups can't wait to find out.

Finding Gold In An Unfavored Space: Servier And MicroRNA Start Up Miragen In CV Deal

Starting with a $45 million upfront, the potential value of this deal, which centers on three pre-clinical cardiovascular targets, could reach up to $1 billion, if the companies meet regulatory and commercial milestones.

Alnylam Shifts To Product-Focused Strategy As RNAi Platform Takes A Hit

Alnylam Pharmaceuticals' strategy announcement on Jan. 7 was “a transformation,” CEO John Maraganore said in an interview at the J.P. Morgan Healthcare Conference, emphasizing that he has “never been more excited” about the prospects for his company.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV002969

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel